首页 > 最新文献

American journal of clinical and experimental immunology最新文献

英文 中文
Comparison of expression of CD1a and CD68 markers in skin leishmaniasis samples with positive and negative Leishman body. 利什曼体阳性和阴性皮肤样品中CD1a和CD68标记物表达的比较
Q4 IMMUNOLOGY Pub Date : 2021-08-15 eCollection Date: 2021-01-01
Fataneh Farokhpour, Parvin Rajabi, Bahare Abtahi Naeini, Azar Naimi

Background: Leishmaniasis is one of the most important infectious illnesses around the world. Given the high commonness of this disease, specifically its skin type in Iran and due to the role of the Leishman bodies in diagnosis, the aim of present study was evaluating the expression of two CD1a and CD68 markers in cutaneous leishmaniasis lesions with and without Leishman bodies.

Methods: In this case-control study, 70 skin samples of patients with cutaneous leishmaniasis (35 patients with Leishman body as case group and 35 patients without Leishman boy as control group) were investigated during 2018-2019. The expression of CD1a and CD68 markers and immunohistochemistry staining (IHC) were investigated in this study.

Results: The expression of CD1a in the group with Leishman body was significantly higher than group without Leishman body (P=0.01), but there was no significant difference between groups as expression of CD68 (P=0.40). The frequency of hyperkeratosis, parakeratosis, exocytosis, acanthosis, spongiosis, hydropic degeneration of basal cell layer, lichenoid reaction, pseudoepitheliomatous hyperplasia, ulcer, thinning of the epidermis, mononuclear cells, and extension of inflammation into lower dermis in the group with Leishman body was higher than group without Leishman body (P<0.05).

Conclusion: The expression of CD1a and other morphological findings help to diagnose the difference between leishmaniasis with and without Leishman body.

背景:利什曼病是世界上最重要的传染病之一。考虑到该病的高度常见性,特别是其在伊朗的皮肤类型,以及利什曼体在诊断中的作用,本研究的目的是评估两种CD1a和CD68标记物在伴有和不伴有利什曼体的皮肤利什曼病病变中的表达。方法:采用病例-对照研究方法,对2018-2019年皮肤利什曼病患者皮肤样本70例(伴有利什曼体患者35例为病例组,未伴有利什曼男孩患者35例为对照组)进行调查。本研究观察了CD1a和CD68标志物的表达及免疫组化染色(IHC)。结果:有利什曼体组CD1a表达显著高于无利什曼体组(P=0.01),而CD68表达无显著差异(P=0.40)。利什曼体组角化过度、角化不全、胞吐、棘层增生、海绵状病、基底细胞层水样变性、地衣样反应、假上皮瘤性增生、溃疡、表皮变薄、单核细胞、炎症向真皮下层延伸的频率高于非利什曼体组(p)。CD1a的表达和其他形态学结果有助于诊断有无利什曼体的利什曼病的差异。
{"title":"Comparison of expression of CD1a and CD68 markers in skin leishmaniasis samples with positive and negative Leishman body.","authors":"Fataneh Farokhpour,&nbsp;Parvin Rajabi,&nbsp;Bahare Abtahi Naeini,&nbsp;Azar Naimi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Leishmaniasis is one of the most important infectious illnesses around the world. Given the high commonness of this disease, specifically its skin type in Iran and due to the role of the Leishman bodies in diagnosis, the aim of present study was evaluating the expression of two CD1a and CD68 markers in cutaneous leishmaniasis lesions with and without Leishman bodies.</p><p><strong>Methods: </strong>In this case-control study, 70 skin samples of patients with cutaneous leishmaniasis (35 patients with Leishman body as case group and 35 patients without Leishman boy as control group) were investigated during 2018-2019. The expression of CD1a and CD68 markers and immunohistochemistry staining (IHC) were investigated in this study.</p><p><strong>Results: </strong>The expression of CD1a in the group with Leishman body was significantly higher than group without Leishman body (P=0.01), but there was no significant difference between groups as expression of CD68 (P=0.40). The frequency of hyperkeratosis, parakeratosis, exocytosis, acanthosis, spongiosis, hydropic degeneration of basal cell layer, lichenoid reaction, pseudoepitheliomatous hyperplasia, ulcer, thinning of the epidermis, mononuclear cells, and extension of inflammation into lower dermis in the group with Leishman body was higher than group without Leishman body (P<0.05).</p><p><strong>Conclusion: </strong>The expression of CD1a and other morphological findings help to diagnose the difference between leishmaniasis with and without Leishman body.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 2","pages":"56-62"},"PeriodicalIF":0.0,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449155/pdf/ajcei0010-0056.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39467721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of a cow's milk-free diet on asthma control in children: a quasi-experimental study. 无牛奶饮食对儿童哮喘控制的影响:一项准实验研究。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Sepideh Darougar, Mahboubeh Mansouri, Solmaz Hassani, Mohammad Reza Sohrabi, Paniz Hashemitari

Background: Food allergy which usually develops in the first year of life is a risk factor for persistent asthma in young children. Cow's milk has been demonstrated to be the most commonly identified food allergen in children. Considering the central role of non-IgE-mediated food allergies in the development of hidden gastroesophageal reflux and consequently asthma, we evaluated the effect of eliminating food allergens to better control asthma.

Method: A total of eighty infants and children up to the age of 12 referred to the Asthma Clinic of Mofid Children Hospital for a period of one year were enrolled in this study. In those patients whose asthma remained uncontrolled (Childhood Asthma Control Test ≤19) despite a 2-week period of treatment, we advocated a 2-week-diet based on eliminating cow's milk in conjunction with asthma conventional therapy. For breast-fed infants, mothers were requested to eliminate these products from their daily intake regimens and for formula-fed infants, the elemental based formula was started.

Results: Three of the patients were lost in follow-up and six of them were excluded from the study because of non-compliance. The Asthma Control Test score which was less than or equal to 19 in the entire study population, increased to 20 or more after we began a diet based on the elimination of cow's milk in all but 13 participants.

Conclusion: To conclude, the results were promising, demonstrating that a cow's milk protein elimination diet is a prudent approach in the management of patients with recalcitrant asthma, and can be considered as the missing link in asthma treatment.

背景:食物过敏通常发生在生命的第一年,是幼儿持续性哮喘的危险因素。牛奶已被证明是儿童中最常见的食物过敏原。考虑到非ige介导的食物过敏在隐性胃食管反流和哮喘发展中的核心作用,我们评估了消除食物过敏原对更好地控制哮喘的作用。方法:选取Mofid儿童医院哮喘门诊就诊1年的80例12岁以下婴幼儿为研究对象。在治疗2周后哮喘仍未得到控制(儿童哮喘控制试验≤19)的患者中,我们提倡在哮喘常规治疗的基础上进行2周不喝牛奶的饮食。对于母乳喂养的婴儿,要求母亲将这些产品从日常摄入方案中剔除,而对于配方奶喂养的婴儿,则开始使用元素基础配方奶粉。结果:3例患者失访,6例患者因不遵医嘱被排除在研究之外。在整个研究人群中,哮喘控制测试得分低于或等于19分,在我们开始一种基于消除牛奶的饮食后,除13名参与者外,所有参与者的哮喘控制测试得分都增加到20分或更多。结论:总之,结果是有希望的,表明牛奶蛋白消除饮食是治疗顽固性哮喘患者的一种谨慎的方法,可以被认为是哮喘治疗中缺失的环节。
{"title":"The effect of a cow's milk-free diet on asthma control in children: a quasi-experimental study.","authors":"Sepideh Darougar,&nbsp;Mahboubeh Mansouri,&nbsp;Solmaz Hassani,&nbsp;Mohammad Reza Sohrabi,&nbsp;Paniz Hashemitari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Food allergy which usually develops in the first year of life is a risk factor for persistent asthma in young children. Cow's milk has been demonstrated to be the most commonly identified food allergen in children. Considering the central role of non-IgE-mediated food allergies in the development of hidden gastroesophageal reflux and consequently asthma, we evaluated the effect of eliminating food allergens to better control asthma.</p><p><strong>Method: </strong>A total of eighty infants and children up to the age of 12 referred to the Asthma Clinic of Mofid Children Hospital for a period of one year were enrolled in this study. In those patients whose asthma remained uncontrolled (Childhood Asthma Control Test ≤19) despite a 2-week period of treatment, we advocated a 2-week-diet based on eliminating cow's milk in conjunction with asthma conventional therapy. For breast-fed infants, mothers were requested to eliminate these products from their daily intake regimens and for formula-fed infants, the elemental based formula was started.</p><p><strong>Results: </strong>Three of the patients were lost in follow-up and six of them were excluded from the study because of non-compliance. The Asthma Control Test score which was less than or equal to 19 in the entire study population, increased to 20 or more after we began a diet based on the elimination of cow's milk in all but 13 participants.</p><p><strong>Conclusion: </strong>To conclude, the results were promising, demonstrating that a cow's milk protein elimination diet is a prudent approach in the management of patients with recalcitrant asthma, and can be considered as the missing link in asthma treatment.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"8-16"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012302/pdf/ajcei0010-0008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25558486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up. x连锁无球蛋白血症:ınvestigation临床和实验室发现,新的基因突变和预防ınfective并发症的长期随访。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
İlke Yıldırım, Ezgi Topyıldız, Raziye Burcu Güven Bilgin, Ayça Aykut, Asude Durmaz, Neslihan Edeer Karaca, Guzide Aksu, Necil Kutukculer

Introduction-Objective: X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease predominantly with antibody deficiency and characterized by recurrent pyogenic infections, absence of B cells and agammaglobulinemia. In this study, it is aimed to review the demographic data of our XLA patients and examine the frequency of severe bacterial and mild infections and benefits of immunoglobulin replacement therapies to reduce the rate of infections. In addition, correlations between genotypic results and clinical and laboratory findings were searched.

Patients and methods: In this study, 20 patients who were followed-up between 1995-2019 and diagnosed with XLA by flow cytometric and genetic tests were included. Demographic data, symptoms at admission and follow-up, laboratory data and radiologic imaging findings, previous infections, immunoglobulin replacement treatments, and genetic analysis results of the patients were recorded.

Results: All patients in the study were male and the mean age of onset of symptoms was 60 months. The mean age at diagnosis was 72 months. A total of 19 different mutations were identified in the Bruton-tyrosine kinase gene, six of them were novel. Our eldest patient was 34 years old and the longest follow-up period was 24 years. Respiratory tract infections were the most common in the patients, only 35% of the causative agents were found in sputum cultures and H. influenzae type b (57.8%) was isolated most frequently. Both intravenous and subcutaneous immunoglobulin replacement therapies significantly reduced the number of severe bacterial infections and other mild infections.

Conclusion: XLA is a rare pediatric primary immunodeficiency disease and affected individuals require lifelong immunoglobulin replacement therapy. Immunoglobulin replacement prevents life-threatening infections and dramatically increases survival rates. The patients with regular treatment and follow-up, reach adulthood and has a high quality of life.

简介-目的:x -连锁无球蛋白血症(XLA)是一种以抗体缺乏为主的原发性免疫缺陷疾病,以反复化脓性感染、B细胞缺乏和无球蛋白血症为特征。在这项研究中,目的是回顾我们的XLA患者的人口统计数据,检查严重细菌感染和轻度感染的频率,以及免疫球蛋白替代疗法降低感染率的益处。此外,研究了基因型结果与临床和实验室结果之间的相关性。患者和方法:本研究纳入了1995-2019年间随访并通过流式细胞术和基因检测诊断为XLA的20例患者。记录患者的人口学资料、入院和随访时的症状、实验室资料和影像学表现、既往感染、免疫球蛋白替代治疗和遗传分析结果。结果:本组患者均为男性,平均发病年龄为60个月。诊断时的平均年龄为72个月。布鲁顿酪氨酸激酶基因共发现19个不同的突变,其中6个为新突变。患者年龄最大,34岁,最长随访时间24年。呼吸道感染最为常见,痰培养中仅检出35%的病原菌,以b型流感嗜血杆菌(57.8%)检出最多。静脉注射和皮下免疫球蛋白替代疗法均可显著减少严重细菌感染和其他轻度感染的数量。结论:XLA是一种罕见的儿童原发性免疫缺陷疾病,患者需要终身免疫球蛋白替代治疗。免疫球蛋白替代可预防危及生命的感染,并显著提高生存率。患者经定期治疗和随访,达到成年期,生活质量高。
{"title":"X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.","authors":"İlke Yıldırım,&nbsp;Ezgi Topyıldız,&nbsp;Raziye Burcu Güven Bilgin,&nbsp;Ayça Aykut,&nbsp;Asude Durmaz,&nbsp;Neslihan Edeer Karaca,&nbsp;Guzide Aksu,&nbsp;Necil Kutukculer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Introduction-Objective: X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease predominantly with antibody deficiency and characterized by recurrent pyogenic infections, absence of B cells and agammaglobulinemia. In this study, it is aimed to review the demographic data of our XLA patients and examine the frequency of severe bacterial and mild infections and benefits of immunoglobulin replacement therapies to reduce the rate of infections. In addition, correlations between genotypic results and clinical and laboratory findings were searched.</p><p><strong>Patients and methods: </strong>In this study, 20 patients who were followed-up between 1995-2019 and diagnosed with XLA by flow cytometric and genetic tests were included. Demographic data, symptoms at admission and follow-up, laboratory data and radiologic imaging findings, previous infections, immunoglobulin replacement treatments, and genetic analysis results of the patients were recorded.</p><p><strong>Results: </strong>All patients in the study were male and the mean age of onset of symptoms was 60 months. The mean age at diagnosis was 72 months. A total of 19 different mutations were identified in the Bruton-tyrosine kinase gene, six of them were novel. Our eldest patient was 34 years old and the longest follow-up period was 24 years. Respiratory tract infections were the most common in the patients, only 35% of the causative agents were found in sputum cultures and H. influenzae type b (57.8%) was isolated most frequently. Both intravenous and subcutaneous immunoglobulin replacement therapies significantly reduced the number of severe bacterial infections and other mild infections.</p><p><strong>Conclusion: </strong>XLA is a rare pediatric primary immunodeficiency disease and affected individuals require lifelong immunoglobulin replacement therapy. Immunoglobulin replacement prevents life-threatening infections and dramatically increases survival rates. The patients with regular treatment and follow-up, reach adulthood and has a high quality of life.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012299/pdf/ajcei0010-0037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25560909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The CCL28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms. 肠易激综合征患者血清CCL28水平升高,且与临床症状相关。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Farshad Sheikhesmaili, Ali Jalili, Elmira Taghizadeh, Shohreh Fakhari, Khashaiar Jalili, Ebrahim Ghaderi, Ezatollah Rahimi

Background: Inflammation and inflammatory mediators have been proposed to be key players in the pathobiology of Irritable bowel syndrome (IBS. The chemokine CCL28 plays a role in the trafficking of inflammatory cells into mucosal tissues. However, its levels in patients with IBS has not been yet elucidated.

Method: In this study, the levels of CCL28 were measured in the serum of 41 patients with IBS and 41 age- and gender-matched normal individuals using Elisa. Then, the receiver operating characteristic (ROC) curve was conducted to assess the diagnostic value of CCL28.

Results: Our data showed that the levels of CCL28 are significantly elevated in patients with IBS compared to the control donors. Moreover, we observed that the level of CCL28 is associated with many clinical symptoms such as constipation, diarrhea, and abdominal pain. The area under the ROC curve was 0.71 (95% confidential interval, 0.598-0.823), the sensitivity and specificity of CCL28 for the diagnosis of IBS patients were 68.3% and 70.7%, respectively with a cut off of 278.9 ng/mL.

Conclusions: We demonstrated that CCL28 is elevated in patients with IBS and correlates with clinical findings, indicating that CCL28 might be an appropriate biomarker for the diagnosis of IBS; however, further studies are necessary.

背景:炎症和炎症介质被认为是肠易激综合征(IBS)病理生物学的关键因素。趋化因子CCL28在炎性细胞进入粘膜组织的运输中起作用。然而,其在肠易激综合征患者中的水平尚未阐明。方法:采用Elisa法检测41例IBS患者和41例年龄、性别匹配的正常人血清中CCL28的水平。然后采用受试者工作特征(ROC)曲线评价CCL28的诊断价值。结果:我们的数据显示,与对照组相比,IBS患者的CCL28水平显著升高。此外,我们观察到CCL28的水平与许多临床症状有关,如便秘、腹泻和腹痛。ROC曲线下面积为0.71(95%可信区间0.598-0.823),CCL28诊断IBS患者的敏感性和特异性分别为68.3%和70.7%,截断值为278.9 ng/mL。结论:我们证明CCL28在IBS患者中升高,并与临床表现相关,表明CCL28可能是IBS诊断的合适生物标志物;然而,还需要进一步的研究。
{"title":"The CCL28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms.","authors":"Farshad Sheikhesmaili,&nbsp;Ali Jalili,&nbsp;Elmira Taghizadeh,&nbsp;Shohreh Fakhari,&nbsp;Khashaiar Jalili,&nbsp;Ebrahim Ghaderi,&nbsp;Ezatollah Rahimi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and inflammatory mediators have been proposed to be key players in the pathobiology of Irritable bowel syndrome (IBS. The chemokine CCL28 plays a role in the trafficking of inflammatory cells into mucosal tissues. However, its levels in patients with IBS has not been yet elucidated.</p><p><strong>Method: </strong>In this study, the levels of CCL28 were measured in the serum of 41 patients with IBS and 41 age- and gender-matched normal individuals using Elisa. Then, the receiver operating characteristic (ROC) curve was conducted to assess the diagnostic value of CCL28.</p><p><strong>Results: </strong>Our data showed that the levels of CCL28 are significantly elevated in patients with IBS compared to the control donors. Moreover, we observed that the level of CCL28 is associated with many clinical symptoms such as constipation, diarrhea, and abdominal pain. The area under the ROC curve was 0.71 (95% confidential interval, 0.598-0.823), the sensitivity and specificity of CCL28 for the diagnosis of IBS patients were 68.3% and 70.7%, respectively with a cut off of 278.9 ng/mL.</p><p><strong>Conclusions: </strong>We demonstrated that CCL28 is elevated in patients with IBS and correlates with clinical findings, indicating that CCL28 might be an appropriate biomarker for the diagnosis of IBS; however, further studies are necessary.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"23-29"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012301/pdf/ajcei0010-0023.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25560907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary neutrophil glatinase-associated lipocalin level (uNGAL) may predict the severity of congenital hydronephrosis in infants. 尿中性粒细胞glatinase-associated lipocalin水平(uNGAL)可以预测婴儿先天性肾积水的严重程度。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Rahimpour Amiri, Hiwa Hosseini, Zahra Sanaei, Saba Shamahmoudi, Ghasem Solgi

Clinical findings suggest that the urinary neutrophil gelatinase-associated lipocalin (uNGAL) level may be a highly sensitive biomarker and predictor of progressive tubular and glomerular injury. This cross-sectional study aimed to determine the predictive power of uNGAL in infants with congenital hydronephrosis. Forty-five children (30 males and 15 females) under the age of two with congenital obstructive uropathy were evaluated for urinary levels of creatinine, uNGAL and uNGAL/uCreatinine (Cr) ratio. Totally, 62.2% of patients had mild, 15.6% had moderate and 22.2% had severe hydronephrosis. We observed a higher significantly uNGAL level in cases with severe form than cases with mild to moderate forms (P=0.002). Also, infants with severe hydronephrosis showed a higher ratio of uNGAL/uCr compared with mild to moderate cases (P=0.006). Correlation analysis showed a significant inverse correlation between uCr levels and pelvic diameter (P=0.002) and direct correlations between uNGAL and uNGAL/uCr ratio and pelvic diameter (P<0.001). By defining a cut-off point of 73.7 ng/ml for uNGAL in ROC analysis, we observed a sensitivity of 70.0% and a specificity of 91.4% forthe prediction of severe hydronephrosis. Our results indicate the potential predictive valueof uNGAL and uNGAL/uCr ratio for hydronephrosis and, more importantly, for discrimination of the severe hydronephrosis from mild to moderate forms.

临床研究结果表明,尿中性粒细胞明胶酶相关脂钙蛋白(uNGAL)水平可能是一个高度敏感的生物标志物和进行性肾小管和肾小球损伤的预测指标。本横断面研究旨在确定uNGAL对先天性肾积水婴儿的预测能力。对45例2岁以下先天性梗阻性尿病患儿(男30例,女15例)进行尿肌酐、uNGAL及uNGAL/ ucreatiine (Cr)比值测定。62.2%为轻度,15.6%为中度,22.2%为重度肾积水。我们观察到重症患者的uNGAL水平明显高于轻中度患者(P=0.002)。重度肾积水患儿uNGAL/uCr比值高于轻中度患儿(P=0.006)。相关分析显示,uCr水平与盆腔直径呈显著负相关(P=0.002), uNGAL及uNGAL/uCr比值与盆腔直径呈正相关(P=0.002)
{"title":"Urinary neutrophil glatinase-associated lipocalin level (uNGAL) may predict the severity of congenital hydronephrosis in infants.","authors":"Rahimpour Amiri,&nbsp;Hiwa Hosseini,&nbsp;Zahra Sanaei,&nbsp;Saba Shamahmoudi,&nbsp;Ghasem Solgi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clinical findings suggest that the urinary neutrophil gelatinase-associated lipocalin (uNGAL) level may be a highly sensitive biomarker and predictor of progressive tubular and glomerular injury. This cross-sectional study aimed to determine the predictive power of uNGAL in infants with congenital hydronephrosis. Forty-five children (30 males and 15 females) under the age of two with congenital obstructive uropathy were evaluated for urinary levels of creatinine, uNGAL and uNGAL/uCreatinine (Cr) ratio. Totally, 62.2% of patients had mild, 15.6% had moderate and 22.2% had severe hydronephrosis. We observed a higher significantly uNGAL level in cases with severe form than cases with mild to moderate forms (P=0.002). Also, infants with severe hydronephrosis showed a higher ratio of uNGAL/uCr compared with mild to moderate cases (P=0.006). Correlation analysis showed a significant inverse correlation between uCr levels and pelvic diameter (P=0.002) and direct correlations between uNGAL and uNGAL/uCr ratio and pelvic diameter (P<0.001). By defining a cut-off point of 73.7 ng/ml for uNGAL in ROC analysis, we observed a sensitivity of 70.0% and a specificity of 91.4% forthe prediction of severe hydronephrosis. Our results indicate the potential predictive valueof uNGAL and uNGAL/uCr ratio for hydronephrosis and, more importantly, for discrimination of the severe hydronephrosis from mild to moderate forms.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012300/pdf/ajcei0010-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25558485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma. Ab-Interno XEN植入术治疗原发性闭角型青光眼的并发症。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Samuel Asanad, Sachin Kalarn, Mona A Kaleem

The XEN Gel Stent offers a unique Ab-interno approach for managing glaucoma and has shown a favorable risk profile relative to traditional trabeculectomy. XEN implantation has almost exclusively been reported in patients with open angle glaucoma and data in patients with angle closure glaucoma is limited. We report a postoperative complication of the XEN Gel Stent in a patient with primary angle closure glaucoma. An 86-year-old man with primary angle closure glaucoma underwent combined phacoemulsification and XEN implantation. After approximately two months, intraocular pressure was elevated and the stent was occluded by iris pigmentary deposits, traversing from the proximal to the distal conjunctival ends of the stent. Using an Ab-interno approach, the implant was successfully explanted, and the patient's intraocular pressure was notably lowered.

XEN凝胶支架为治疗青光眼提供了一种独特的Ab-interno方法,与传统的小梁切除术相比,它具有良好的风险。XEN植入术几乎只在开角型青光眼患者中有报道,而闭角型青光眼患者的数据有限。我们报告一例原发性闭角型青光眼患者的XEN凝胶支架术后并发症。一例86岁原发性闭角型青光眼患者行超声乳化术联合XEN植入术。大约两个月后,眼压升高,支架被虹膜色素沉积物阻塞,从支架的近端到远端结膜。采用Ab-interno入路,植入物成功取出,患者眼压明显降低。
{"title":"Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma.","authors":"Samuel Asanad,&nbsp;Sachin Kalarn,&nbsp;Mona A Kaleem","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The XEN Gel Stent offers a unique Ab-interno approach for managing glaucoma and has shown a favorable risk profile relative to traditional trabeculectomy. XEN implantation has almost exclusively been reported in patients with open angle glaucoma and data in patients with angle closure glaucoma is limited. We report a postoperative complication of the XEN Gel Stent in a patient with primary angle closure glaucoma. An 86-year-old man with primary angle closure glaucoma underwent combined phacoemulsification and XEN implantation. After approximately two months, intraocular pressure was elevated and the stent was occluded by iris pigmentary deposits, traversing from the proximal to the distal conjunctival ends of the stent. Using an Ab-interno approach, the implant was successfully explanted, and the patient's intraocular pressure was notably lowered.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"44-47"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012303/pdf/ajcei0010-0044.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25560910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating sedative effects of dexmedetomidine and morphine in the patients with opioid use disorder undergoing cataract surgery. 评价右美托咪定和吗啡在阿片类药物使用障碍白内障手术患者中的镇静作用。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Dariush Moradi Farsani, Keyvan Ghadimi, Raana Abrishamkar, Kamran Montazeri, Alireza Peyman

Background: Considering that patients with opioid dependence are at higher risk of inadequate sedation during operations, and the rescue analgesia in these patients are usually greater than the general population; the aim of this study was comparison of sedation quality of dexmedetomidine and morphine in patients with opioid use disorder undergoing cataract surgery.

Methods: This clinical trial was conducted on 60 patients with opioid use disorder underwent cataract surgery that were referred to Feiz Hospital, Isfahan, Iran in 2018. Patients were randomly divided into two groups as the dexmedetomidine group started 1 μg/kg dexmedetomidine in 10 minutes before surgery and then continued with 0.5 μg/kg/h while the morphine group received 0.1 mg/kg of morphine before surgery. Sedation score, pain intensity, hemodynamic parameters, analgesic request and side effects were compared in the two groups.

Results: There was no significant differences between groups based on Ramsay score before, during and after surgery (P > 0.05), the pain intensity in the morphine group was significantly lower during the recovery period than dexmedetomidine group, the duration of recovery and sedation in the morphine group was significantly more than the dexmedetomidine group, and nausea and vomiting and eye pain in the morphine group were significantly higher than dexmedetomidine (P < 0.05).

Conclusion: Morphine usage was more effective in pain relief than dexmedetomidine in patients with opioid use disorder undergoing cataract surgery, but the complications and recovery time were higher in morphine usage. Also the sedation was similar in both groups.

背景:考虑到阿片类药物依赖患者术中镇静不充分的风险较高,且该类患者的抢救镇痛往往大于一般人群;本研究的目的是比较右美托咪定和吗啡在阿片类药物使用障碍白内障手术患者中的镇静质量。方法:对2018年转介至伊朗伊斯法罕菲兹医院行白内障手术的60例阿片类药物使用障碍患者进行临床试验。将患者随机分为两组,右美托咪定组术前10分钟开始给予右美托咪定1 μg/kg,术后继续给予0.5 μg/kg/h,吗啡组术前给予0.1 mg/kg吗啡。比较两组患者的镇静评分、疼痛强度、血流动力学参数、镇痛要求及不良反应。结果:各组术前、术中、术后Ramsay评分差异无统计学意义(P > 0.05),吗啡组恢复期疼痛强度显著低于右美托咪定组,吗啡组恢复期疼痛持续时间及镇静时间显著高于右美托咪定组,恶心呕吐及眼痛发生率显著高于右美托咪定组(P < 0.05)。结论:吗啡对阿片类药物使用障碍白内障手术患者疼痛的缓解效果优于右美托咪定,但吗啡的并发症和恢复时间较高。两组的镇静效果相似。
{"title":"Evaluating sedative effects of dexmedetomidine and morphine in the patients with opioid use disorder undergoing cataract surgery.","authors":"Dariush Moradi Farsani,&nbsp;Keyvan Ghadimi,&nbsp;Raana Abrishamkar,&nbsp;Kamran Montazeri,&nbsp;Alireza Peyman","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Considering that patients with opioid dependence are at higher risk of inadequate sedation during operations, and the rescue analgesia in these patients are usually greater than the general population; the aim of this study was comparison of sedation quality of dexmedetomidine and morphine in patients with opioid use disorder undergoing cataract surgery.</p><p><strong>Methods: </strong>This clinical trial was conducted on 60 patients with opioid use disorder underwent cataract surgery that were referred to Feiz Hospital, Isfahan, Iran in 2018. Patients were randomly divided into two groups as the dexmedetomidine group started 1 μg/kg dexmedetomidine in 10 minutes before surgery and then continued with 0.5 μg/kg/h while the morphine group received 0.1 mg/kg of morphine before surgery. Sedation score, pain intensity, hemodynamic parameters, analgesic request and side effects were compared in the two groups.</p><p><strong>Results: </strong>There was no significant differences between groups based on Ramsay score before, during and after surgery (P > 0.05), the pain intensity in the morphine group was significantly lower during the recovery period than dexmedetomidine group, the duration of recovery and sedation in the morphine group was significantly more than the dexmedetomidine group, and nausea and vomiting and eye pain in the morphine group were significantly higher than dexmedetomidine (P < 0.05).</p><p><strong>Conclusion: </strong>Morphine usage was more effective in pain relief than dexmedetomidine in patients with opioid use disorder undergoing cataract surgery, but the complications and recovery time were higher in morphine usage. Also the sedation was similar in both groups.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"30-36"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012304/pdf/ajcei0010-0030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25560908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between matrix metalloproteinase-9 and some clinicopathological prognostic factors of breast carcinoma. 基质金属蛋白酶-9与乳腺癌临床病理预后的关系。
Q4 IMMUNOLOGY Pub Date : 2021-02-15 eCollection Date: 2021-01-01
Fereshteh Mohammadizadeh, Mahsa Bagherian-Dehkordia

Background: Matrix metalloproteinase-9 (MMP-9), an enzyme with major role in remodeling of extracellular matrix, has been the focus of attention in some previous studies in the field of breast cancer. In the current study the relationship between matrix metalloproteinase-9 and some clinicopathological factors of breast carcinoma has also been evaluated.

Methods: Formalin-fixed and paraffin-embedded tissue specimens from three groups including 40 invasive breast carcinoma (tumor group) and their adjacent normal tissue (tumor control), as well as 40 normal mammoplasty specimens (normal control) were studied. The samples were from the pathology archive of Alzahra Hospital, Isfahan, Iran, from 2016 to 2018. The status of intraepithelial MMP-9 were studied and compared in these three groups using immunohistochemistry.

Results: The extent of intraepithelial MMP-9 immunostaining in all positive specimens was 100%. The results of intraepithelial MMP-9 staining intensity was as follow: 12.5% strong, 27.5% moderate, 27.5% mild, and 32.5% negative in tumor group; 17.5% strong, 22.5% moderate, 32.5% mild, and 27.5% negative in tumor control group; and 10% strong, 40% moderate, 27.5% mild, and 22.5% negative in normal control group. Intraepithelial MMP-9 immunostaining intensity showed significant difference between tumor and tumor control groups (P<0.001). Intraepithelial MMP-9 immunostaining intensity showed no significant difference between tumor and normal control groups, and between tumor control and normal control groups (P>0.05). No significant relationship was seen between intraepithelial MMP-9 immunostaining intensity and age, tumor size, tumor grade, and lymph node status in tumor group (P>0.05).

Conclusion: Intraepithelial MMP-9 expression increases in some breast carcinomas. Normal breast tissue adjacent to carcinoma does not show such increase. However, intraepithelial MMP-9 expression in breast carcinoma does not show any significant relationship with age, tumor size, tumor grade, and lymph node status.

背景:基质金属蛋白酶-9 (Matrix metalloproteinase-9, MMP-9)是一种参与细胞外基质重塑的重要酶,是乳腺癌研究的热点。在目前的研究中,基质金属蛋白酶-9与乳腺癌的一些临床病理因素的关系也得到了评价。方法:选取40例浸润性乳腺癌(肿瘤组)及其邻近正常组织(肿瘤对照组)和40例正常乳房成形术标本(正常对照组)进行福尔马林固定和石蜡包埋组织标本的研究。样本来自伊朗伊斯法罕Alzahra医院2016年至2018年的病理档案。利用免疫组织化学方法研究并比较三组上皮内MMP-9的状态。结果:所有阳性标本上皮内MMP-9免疫染色率均为100%。上皮内MMP-9染色强度:肿瘤组为12.5%强、27.5%中度、27.5%轻度、32.5%阴性;肿瘤对照组17.5%为强、22.5%为中度、32.5%为轻度、27.5%为阴性;正常对照组为强10%,中度40%,轻度27.5%,阴性22.5%。肿瘤组与肿瘤对照组间上皮内MMP-9免疫染色强度差异有统计学意义(P0.05)。肿瘤组患者上皮内MMP-9免疫染色强度与年龄、肿瘤大小、肿瘤分级、淋巴结状况无显著相关性(P>0.05)。结论:上皮内MMP-9表达在部分乳腺癌中升高。癌旁的正常乳腺组织没有这种增加。然而,上皮内MMP-9在乳腺癌中的表达与年龄、肿瘤大小、肿瘤分级和淋巴结状态没有任何显著关系。
{"title":"Relationship between matrix metalloproteinase-9 and some clinicopathological prognostic factors of breast carcinoma.","authors":"Fereshteh Mohammadizadeh,&nbsp;Mahsa Bagherian-Dehkordia","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Matrix metalloproteinase-9 (MMP-9), an enzyme with major role in remodeling of extracellular matrix, has been the focus of attention in some previous studies in the field of breast cancer. In the current study the relationship between matrix metalloproteinase-9 and some clinicopathological factors of breast carcinoma has also been evaluated.</p><p><strong>Methods: </strong>Formalin-fixed and paraffin-embedded tissue specimens from three groups including 40 invasive breast carcinoma (tumor group) and their adjacent normal tissue (tumor control), as well as 40 normal mammoplasty specimens (normal control) were studied. The samples were from the pathology archive of Alzahra Hospital, Isfahan, Iran, from 2016 to 2018. The status of intraepithelial MMP-9 were studied and compared in these three groups using immunohistochemistry.</p><p><strong>Results: </strong>The extent of intraepithelial MMP-9 immunostaining in all positive specimens was 100%. The results of intraepithelial MMP-9 staining intensity was as follow: 12.5% strong, 27.5% moderate, 27.5% mild, and 32.5% negative in tumor group; 17.5% strong, 22.5% moderate, 32.5% mild, and 27.5% negative in tumor control group; and 10% strong, 40% moderate, 27.5% mild, and 22.5% negative in normal control group. Intraepithelial MMP-9 immunostaining intensity showed significant difference between tumor and tumor control groups (P<0.001). Intraepithelial MMP-9 immunostaining intensity showed no significant difference between tumor and normal control groups, and between tumor control and normal control groups (P>0.05). No significant relationship was seen between intraepithelial MMP-9 immunostaining intensity and age, tumor size, tumor grade, and lymph node status in tumor group (P>0.05).</p><p><strong>Conclusion: </strong>Intraepithelial MMP-9 expression increases in some breast carcinomas. Normal breast tissue adjacent to carcinoma does not show such increase. However, intraepithelial MMP-9 expression in breast carcinoma does not show any significant relationship with age, tumor size, tumor grade, and lymph node status.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 1","pages":"17-22"},"PeriodicalIF":0.0,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012305/pdf/ajcei0010-0017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25560906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID 19 with neurological symptoms, rhabdomyolysis and brain death: a case report. 新冠肺炎合并神经系统症状、横纹肌溶解和脑死亡1例报告
Q4 IMMUNOLOGY Pub Date : 2020-12-15 eCollection Date: 2020-01-01
Amir Aria, Khatereh Forouharnejad, Mozhgan Mortazavi, Ashkan Omidi, Mozhde Askari, Keyvan Ghadimi, Nazlisadat Mashinchi-Asl

Background: In the worldwide, there are the pandemic of the virus coronavirus disease 2019 (COVID-19) and there is no approved treatment for this disease.

Case presentation: This study reported a new case with COVID 19 with neurological symptoms such as headache and loss of consciousness without any symptoms and imaging of COVID 19 in admission but RT-PCR COVID 19 of patient was positive and during hospitalization patient had increasing cerebrospinal fluid (CSF) volume in sub-arachnoid space, micro-hemorrhaging in basal ganglia and down ward cerebellar tonsile herniation in the brain imaging, also there were rhabdomyolysis and thrombotic thrombocytopenic purpura in the lab data. Finally, based on abnormal electroencephalogram (EEG), brain death was diagnosed for patient in end of hospitalization. In the 8th of admission day, the patients died after cardiovascular arrest.

Conclusion: The COVID 19 can be associated with different symptoms such as neurological complication and brain death was unusual complication in COVID19.

背景:在全球范围内,新型冠状病毒病2019 (COVID-19)正在大流行,目前尚无批准的治疗方法。案例介绍:本研究报告1例新发COVID - 19患者,入院时无新冠肺炎症状和影像学,但患者RT-PCR检测COVID - 19阳性,住院期间脑影像学显示蛛网膜下腔脑脊液体积增加,基底节区微出血,小脑扁桃体向下突出。在实验室数据中也有横纹肌溶解和血栓性血小板减少性紫癜。最后根据异常脑电图(EEG)诊断患者在住院末期脑死亡。入院第8天,患者因心血管骤停死亡。结论:新冠肺炎可伴有不同症状,如神经系统并发症,脑死亡是新冠肺炎的罕见并发症。
{"title":"COVID 19 with neurological symptoms, rhabdomyolysis and brain death: a case report.","authors":"Amir Aria, Khatereh Forouharnejad, Mozhgan Mortazavi, Ashkan Omidi, Mozhde Askari, Keyvan Ghadimi, Nazlisadat Mashinchi-Asl","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>In the worldwide, there are the pandemic of the virus coronavirus disease 2019 (COVID-19) and there is no approved treatment for this disease.</p><p><strong>Case presentation: </strong>This study reported a new case with COVID 19 with neurological symptoms such as headache and loss of consciousness without any symptoms and imaging of COVID 19 in admission but RT-PCR COVID 19 of patient was positive and during hospitalization patient had increasing cerebrospinal fluid (CSF) volume in sub-arachnoid space, micro-hemorrhaging in basal ganglia and down ward cerebellar tonsile herniation in the brain imaging, also there were rhabdomyolysis and thrombotic thrombocytopenic purpura in the lab data. Finally, based on abnormal electroencephalogram (EEG), brain death was diagnosed for patient in end of hospitalization. In the 8<sup>th</sup> of admission day, the patients died after cardiovascular arrest.</p><p><strong>Conclusion: </strong>The COVID 19 can be associated with different symptoms such as neurological complication and brain death was unusual complication in COVID19.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"9 5","pages":"114-117"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811927/pdf/ajcei0009-0114.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38775928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience. 膀胱尿路上皮癌三级淋巴结构的当前概念:文献回顾和我们的经验。
Q4 IMMUNOLOGY Pub Date : 2020-12-15 eCollection Date: 2020-01-01
Milena Gulinac, Dorian Dikov, Simeon Lichev, Tsvetelina Velikova

Bladder carcinoma (BC) is one of the most common malignancies of the urinary system in developed countries, with a high number of recurrences. The secondary lymphoid organs (SLO) are crucial for initiating the adaptive immune response. They are developed as a part of a genetically preprogrammed process during embryogenesis. However, SLO's organogenesis can be reduplicated de novo in other tissues by a process termed lymphoid neo-genesis, giving rise to tertiary lymphoid structures (TLS). These well-organized lymphoid structures in cancer are essential modulators of cancer immunologic response, and the histological examination of TLS gave a new strategy for cancer immunotherapy. This review explores the biological and histological characteristics of TLS in muscle non-invasive and invasive BC.

膀胱癌(BC)是发达国家泌尿系统最常见的恶性肿瘤之一,具有很高的复发率。次级淋巴器官(SLO)是启动适应性免疫反应的关键。它们是胚胎发育过程中基因预编程过程的一部分。然而,SLO的器官发生可以在其他组织中通过称为淋巴样新发生的过程重新复制,产生三级淋巴样结构(TLS)。肿瘤中这些组织良好的淋巴样结构是肿瘤免疫反应的重要调节因子,对TLS的组织学检查为肿瘤免疫治疗提供了新的策略。本文综述了肌肉非侵袭性和侵袭性BC中TLS的生物学和组织学特征。
{"title":"Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience.","authors":"Milena Gulinac,&nbsp;Dorian Dikov,&nbsp;Simeon Lichev,&nbsp;Tsvetelina Velikova","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bladder carcinoma (BC) is one of the most common malignancies of the urinary system in developed countries, with a high number of recurrences. The secondary lymphoid organs (SLO) are crucial for initiating the adaptive immune response. They are developed as a part of a genetically preprogrammed process during embryogenesis. However, SLO's organogenesis can be reduplicated de novo in other tissues by a process termed lymphoid neo-genesis, giving rise to tertiary lymphoid structures (TLS). These well-organized lymphoid structures in cancer are essential modulators of cancer immunologic response, and the histological examination of TLS gave a new strategy for cancer immunotherapy. This review explores the biological and histological characteristics of TLS in muscle non-invasive and invasive BC.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"9 5","pages":"64-72"},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811926/pdf/ajcei0009-0064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38775477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of clinical and experimental immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1